Patents by Inventor Hironao Wakabayashi

Hironao Wakabayashi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Recombinant factor VIII having increased stability
    Patent number: 9072722
    Abstract: The present invention relates to a recombinant factor VIII that includes one or more mutations that result in enhanced stability of both factor VIII and factor VIIIa. Methods of making and using the recombinant factor VIII, and pharmaceutical compositions containing the same are also disclosed. The present invention further relates to an isolated nucleic acid molecule that encodes the recombinant factor VIII, as well as DNA expression systems and host cells containing the isolated nucleic acid molecule.
    Type: Grant
    Filed: November 30, 2012
    Date of Patent: July 7, 2015
    Assignee: University of Rochester
    Inventors: Philip J. Fay, Hironao Wakabayashi
  • RECOMBINANT FACTOR VIII HAVING ENHANCED STABILITY FOLLOWING MUTATION AT THE A1-C2 DOMAIN INTERFACE
    Publication number: 20150037301
    Abstract: The invention relates to a recombinant factor VIII that includes one or more mutations at an interface of A1 and C2 domains of recombinant factor VIII. The one or more mutations include substitution of one or more amino acid residues with either a cysteine or an amino acid residue having a higher hydrophobicity. This results in enhanced stability of factor VIII. Methods for making the recombinant factor VIII, pharmaceutical compositions containing the recombinant factor VIII, and use of the recombinant factor VIII for treating hemophilia A are also disclosed.
    Type: Application
    Filed: October 19, 2014
    Publication date: February 5, 2015
    Applicant: UNIVERSITY OF ROCHESTER
    Inventors: Philip J. Fay, Hironao Wakabayashi
  • Recombinant factor VIII having enhanced stability following mutation at the A1-C2 domain interface
    Patent number: 8865154
    Abstract: The invention relates to a recombinant factor VIII that includes one or more mutations at an interface of A1 and C2 domains of recombinant factor VIII. The one or more mutations include substitution of one or more amino acid residues with either a cysteine or an amino acid residue having a higher hydrophobicity. This results in enhanced stability of factor VIII. Methods for making the recombinant factor VIII, pharmaceutical compositions containing the recombinant factor VIII, and use of the recombinant factor VIII for treating hemophilia A are also disclosed.
    Type: Grant
    Filed: December 27, 2013
    Date of Patent: October 21, 2014
    Assignee: University of Rochester
    Inventors: Philip J. Fay, Hironao Wakabayashi
  • RECOMBINANT FACTOR VIII HAVING ENHANCED STABILITY FOLLOWING MUTATION AT THE A1-C2 DOMAIN INTERFACE
    Publication number: 20140120071
    Abstract: The invention relates to a recombinant factor VIII that includes one or more mutations at an interface of A1 and C2 domains of recombinant factor VIII. The one or more mutations include substitution of one or more amino acid residues with either a cysteine or an amino acid residue having a higher hydrophobicity. This results in enhanced stability of factor VIII. Methods for making the recombinant factor VIII, pharmaceutical compositions containing the recombinant factor VIII, and use of the recombinant factor VIII for treating hemophilia A are also disclosed.
    Type: Application
    Filed: December 27, 2013
    Publication date: May 1, 2014
    Applicant: UNIVERSITY OF ROCHESTER
    Inventors: Philip J. FAY, Hironao WAKABAYASHI
  • RECOMBINANT FACTOR VIII HAVING INCREASED STABILITY
    Publication number: 20140056861
    Abstract: The present invention relates to a recombinant factor VIII that includes one or more mutations that result in enhanced stability of both factor VIII and factor VIIIa. Methods of making and using the recombinant factor VIII, and pharmaceutical compositions containing the same are also disclosed. The present invention further relates to an isolated nucleic acid molecule that encodes the recombinant factor VIII, as well as DNA expression systems and host cells containing the isolated nucleic acid molecule.
    Type: Application
    Filed: October 11, 2013
    Publication date: February 27, 2014
    Applicant: University of Rochester
    Inventors: Philip J. Fay, Hironao Wakabayashi
  • Recombinant factor VIII having enhanced stability following mutation at the A1-C2 domain interface
    Patent number: 8637448
    Abstract: The invention relates to a recombinant factor VIII that includes one or more mutations at an interface of A1 and C2 domains of recombinant factor VIII. The one or more mutations include substitution of one or more amino acid residues with either a cysteine or an amino acid residue having a higher hydrophobicity. This results in enhanced stability of factor VIII. Methods for making the recombinant factor VIII, pharmaceutical compositions containing the recombinant factor VIII, and use of the recombinant factor VIII for treating hemophilia A are also disclosed.
    Type: Grant
    Filed: September 13, 2011
    Date of Patent: January 28, 2014
    Assignee: University of Rochester
    Inventors: Philip J. Fay, Hironao Wakabayashi
  • Recombinant factor VIII having increased stability
    Patent number: 8338571
    Abstract: The present invention relates to a recombinant factor VIII that includes one or more mutations that result in enhanced stability of both factor VIII and factor VIIIa. Methods of making and using the recombinant factor VIII, and pharmaceutical compositions containing the same are also disclosed. The present invention further relates to an isolated nucleic acid molecule that encodes the recombinant factor VIII, as well as DNA expression systems and host cells containing the isolated nucleic acid molecule.
    Type: Grant
    Filed: July 25, 2008
    Date of Patent: December 25, 2012
    Assignee: University of Rochester
    Inventors: Philip J. Fay, Hironao Wakabayashi
  • Recombinant factor VIII having reduced inactivation by activated protein C
    Patent number: 8183345
    Abstract: The present invention relates to a recombinant factor VIII that is characterized by one or more mutations within a region surrounding an activated protein C cleavage site, which one or more mutations result in a reduced rate of inactivation by activated protein C. Isolated nucleic acid molecules, recombinant expression vectors, and host cells suitable for expression of the recombinant factor VIII are also disclosed. The recombinant factor VIII can be used for the treatment of clotting disorders, such as hemophilia A.
    Type: Grant
    Filed: July 25, 2008
    Date of Patent: May 22, 2012
    Assignee: University of Rochester
    Inventors: Philip J. Fay, Hironao Wakabayashi, Fatbardha Varfaj
  • RECOMBINANT FACTOR VIII HAVING ENHANCED STABILITY FOLLOWING MUTATION AT THE A1-C2 DOMAIN INTERFACE
    Publication number: 20120065136
    Abstract: The invention relates to a recombinant factor VIII that includes one or more mutations at an interface of A1 and C2 domains of recombinant factor VIII. The one or more mutations include substitution of one or more amino acid residues with either a cysteine or an amino acid residue having a higher hydrophobicity. This results in enhanced stability of factor VIII. Methods for making the recombinant factor VIII, pharmaceutical compositions containing the recombinant factor VIII, and use of the recombinant factor VIII for treating hemophilia A are also disclosed.
    Type: Application
    Filed: September 13, 2011
    Publication date: March 15, 2012
    Applicant: UNIVERSITY OF ROCHESTER
    Inventors: Philip J. FAY, Hironao WAKABAYASHI
  • Recombinant factor VIII having increased specific activity
    Patent number: 7855274
    Abstract: The present invention relates to recombinant factor VIII having a specific activity that is higher than that of the corresponding wild-type factor VIII. The present invention also relates to methods of making and using the recombinant factor VIII. The present invention also relates to an isolated nucleic acid molecule that encodes the recombinant factor VIII, as well as DNA expression systems and host cells containing the isolated nucleic acid molecule.
    Type: Grant
    Filed: December 2, 2004
    Date of Patent: December 21, 2010
    Assignee: University of Rochester
    Inventors: Philip J. Fay, Hironao Wakabayashi
  • RECOMBINANT FACTOR VIII HAVING REDUCED INACTIVATION BY ACTIVATED PROTEIN C
    Publication number: 20090118185
    Abstract: The present invention relates to a recombinant factor VIII that is characterized by one or more mutations within a region surrounding an activated protein C cleavage site, which one or more mutations result in a reduced rate of inactivation by activated protein C. Isolated nucleic acid molecules, recombinant expression vectors, and host cells suitable for expression of the recombinant factor VIII are also disclosed. The recombinant factor VIII can be used for the treatment of clotting disorders, such as hemophilia A.
    Type: Application
    Filed: July 25, 2008
    Publication date: May 7, 2009
    Applicant: UNIVERSITY OF ROCHESTER
    Inventors: Philip J. Fay, Hironao Wakabayashi
  • RECOMBINANT FACTOR VIII HAVING INCREASED STABILITY
    Publication number: 20090118184
    Abstract: The present invention relates to a recombinant factor VIII that includes one or more mutations that result in enhanced stability of both factor VIII and factor VIIIa. Methods of making and using the recombinant factor VIII, and pharmaceutical compositions containing the same are also disclosed. The present invention further relates to an isolated nucleic acid molecule that encodes the recombinant factor VIII, as well as DNA expression systems and host cells containing the isolated nucleic acid molecule.
    Type: Application
    Filed: July 25, 2008
    Publication date: May 7, 2009
    Applicant: UNIVERSITY OF ROCHESTER
    Inventors: Philip J. Fay, Hironao Wakabayashi
  • Recombinant Factor VIII Having Increased Specific Activity
    Publication number: 20070265199
    Abstract: The present invention relates to recombinant factor VIII having a specific activity that is higher than that of the corresponding wild-type factor VIII. The present invention also relates to methods of making and using the recombinant factor VIII. The present invention also relates to an isolated nucleic acid molecule that encodes the recombinant factor VIII, as well as DNA expression systems and host cells containing the isolated nucleic acid molecule.
    Type: Application
    Filed: December 2, 2004
    Publication date: November 15, 2007
    Inventors: Philip Fay, Hironao Wakabayashi